Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.

about

Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.

Item

http://www.wikidata.org/entity/Q41676735

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Different doses of micafungin ...... iversity hospitals in Germany.

@en

type

Item

label

Different doses of micafungin ...... iversity hospitals in Germany.

@en

prefLabel

Different doses of micafungin ...... iversity hospitals in Germany.

@en

P1476

Different doses of micafungin ...... niversity hospitals in Germany

@en

P2093

J J Vehreschild

http://www.w3.org/2001/XMLSchema#string

L Meintker

http://www.w3.org/2001/XMLSchema#string

M J G T Vehreschild

http://www.w3.org/2001/XMLSchema#string

M von Bergwelt-Baildon

http://www.w3.org/2001/XMLSchema#string

S M Heimann

http://www.w3.org/2001/XMLSchema#string

T Schroeder

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes.

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

P304

968-974

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TID.12305

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Werner J Heinz

Oliver A Cornely

P577

2014-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25371351

http://www.w3.org/2001/XMLSchema#string

P921

A' Ghearmailt